CELC (Celcuity) Retained Earnings : $-235.20 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Celcuity Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Celcuity's retained earnings for the quarter that ended in Sep. 2024 was $-235.20 Mil.

Celcuity's quarterly retained earnings declined from Mar. 2024 ($-181.69 Mil) to Jun. 2024 ($-205.41 Mil) and declined from Jun. 2024 ($-205.41 Mil) to Sep. 2024 ($-235.20 Mil).

Celcuity's annual retained earnings declined from Dec. 2021 ($-55.93 Mil) to Dec. 2022 ($-96.30 Mil) and declined from Dec. 2022 ($-96.30 Mil) to Dec. 2023 ($-160.08 Mil).

Celcuity Retained Earnings Historical Data

The historical data trend for Celcuity's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity Retained Earnings Chart

Celcuity Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-16.85

-26.32

-55.93

-96.30

-160.08

Celcuity Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															-141.23	-160.08	-181.69	-205.41	-235.20

Celcuity Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Celcuity (NAS:CELC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Celcuity Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446

Website

https://www.celcuity.com

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Executives

Richard E Buller	director	C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey	director	C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht	director	C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan	director, 10 percent owner, officer: Chief Executive Officer	16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon	director	CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing	director, 10 percent owner, officer: Chief Science Officer, VP	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne	officer: Chief Financial Officer	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin	director	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446